<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02144194</url>
  </required_header>
  <id_info>
    <org_study_id>CRG SE036</org_study_id>
    <nct_id>NCT02144194</nct_id>
  </id_info>
  <brief_title>Maintenance Oral Vinorelbine or Observation After Vinorelbine-Docetaxel First Line Chemotherapy in Advanced Breast Ca</brief_title>
  <acronym>TNM</acronym>
  <official_title>TNM Trial: Upfront Docetaxel [T] and Alternating iv and Oral Vinorelbine [N] Followed, by Either Maintenance Oral Vinorelbine, or Observation for Advanced Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cancer Research Group - Collaborative Group, Beirut, Lebanon.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cancer Research Group - Collaborative Group, Beirut, Lebanon.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This 2 arms study will assess the efficacy and safety of the Vinorelbine-Docetaxel
      combination given as an initial upfront treatment (first line) to all metastatic breast
      cancer patients enrolled. Patients having a disease control following initial treatment, will
      be randomized to either oral Vinorelbine maintenance arm or Observation arm. The trial will
      also compare the efficacy and safety of maintenance oral Vinorelbine versus Observation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To our knowledge, this is the first trial evaluating the role of oral Vinorelbine as a
      maintenance therapy versus observation following a first line treatment with iv/oral
      Vinorelbine+Docetaxel. Eligible patients will be enrolled in the trial to receive 6 cycles of
      iv(D1)/oral(D8) Vinorelbine + Docetaxel. For responding and SD patients, after the 6 cycles,
      they will be randomized either in observation arm or to receive a maintenance chemotherapy
      with oral Vinorelbine. The oral form of the drug was found to be most appropriate for a long
      term treatment allowing to preserve QoL of the patients. Oral Vinorelbine will be
      administered on D1, D8 every 3 weeks during maintenance treatment, until PD, unacceptable
      toxicity or patient refusal to continue. The trial will assess efficacy/safety of initial
      Vinorelbine-Docetaxel combination as well as the benefits of maintenance chemotherapy with
      oral Vinorelbine.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time To Disease Progression of patients who are treated with Vinorelbine-Docetaxel followed by maintenance oral Vinorelbine vs patients treated with Vinorelbine-Docetaxel without maintenance treatment</measure>
    <time_frame>Up to 36 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate</measure>
    <time_frame>Up to 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response</measure>
    <time_frame>Up to 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>Up to 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and percentage of participants with Adverse Events</measure>
    <time_frame>Participants will be followed for the entired duration of the study, an expected average of 60 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>3-Y Overall Survival</measure>
    <time_frame>Up to 36 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">65</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Maintenance treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Initial treatment Vinorelbine-Docetaxel Vinorelbine I.V: 20mg/m2 D1 Docetaxel: 60mg/m2 D1 Vinorelbine Oral: 60mg/m2 D8 Every 3 weeks for 6 cycles
Followed by:
Oral Vinorelbine 60mg/m2 D1, D8 or 80mg/m2 D1, D8 (dose schedule at investigator's discretion) Every 3 weeks until disease progression, unacceptable toxicities or patient refusal to continue</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Observation arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Initial treatment: Vinorelbine-Docetaxel Vinorelbine I.V: 20mg/m2 D1 Docetaxel: 60mg/m2 D1 Vinorelbine Oral: 60mg/m2 D8 Every 3 weeks for 6 cycles
Patients in the observation arm will not be administered any treatment after Vinorelbine-Docetaxel</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vinorelbine-Docetaxel</intervention_name>
    <description>Vinorelbine I.V: 20mg/m2 D1 Docetaxel: 60mg/m2 D1 Vinorelbine Oral: 60mg/m2 D8 Every 3 weeks x 6 cycles</description>
    <arm_group_label>Maintenance treatment</arm_group_label>
    <arm_group_label>Observation arm</arm_group_label>
    <other_name>Navelbine</other_name>
    <other_name>Navelbine IV</other_name>
    <other_name>Navelbine Oral</other_name>
    <other_name>Taxotere</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vinorelbine</intervention_name>
    <description>Oral Vinorelbine 60mg/m2 or 80mg/m2 D1, D8 every 3 weeks until disease progression, unacceptable toxicities or patient refusal to continue (dose schedule is at investigator's discretion)</description>
    <arm_group_label>Maintenance treatment</arm_group_label>
    <other_name>Navelbine Oral</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent

          -  Patients &gt;=18 years of age

          -  Histologically or cytologically confirmed adenocarcinoma of the breast that is now
             metastatic or locally-recurrent and inoperable with curative intent

          -  Measurable and/or non-measurable disease

          -  The patient's primary and/or metastatic tumor is HER2 neu negative

          -  Documented metastatic disease previously untreated with palliative chemotherapy

          -  Adjuvant or neo-adjuvant chemotherapy (including treatment with docetaxel or any other
             chemotherapy) is allowed with a disease free survival of at least 6 months

          -  No symptom or sign of brain metastasis

        Exclusion Criteria:

          -  Operable local recurrence

          -  Ascites or pericardial effusion as only site of metastasis

          -  Symptomatic peripheral neuropathy &gt; grade 1 according to the NCI Common Toxicity
             Criteria

          -  Radiotherapy to all areas of evaluable disease within the previous 4 weeks

          -  Disease significantly affecting absorption

          -  Severe hepatic insufficiency

          -  Patient previously treated with chemotherapy for their metastatic disease
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fadi Farhat, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hammoud Hospital University Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marwan Ghosn, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hotel Dieu De France University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Georges Chahine, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hotel Dieu de France University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joseph Kattan, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hotel Dieu de France University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nizar Bitar, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sahel General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hotel Dieu de France University Hospital</name>
      <address>
        <city>Achrafieh</city>
        <state>Beirut</state>
        <country>Lebanon</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hammoud Hospital University Medical Center</name>
      <address>
        <city>Saida</city>
        <country>Lebanon</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Lebanon</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 15, 2014</study_first_submitted>
  <study_first_submitted_qc>May 19, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 21, 2014</study_first_posted>
  <last_update_submitted>February 7, 2017</last_update_submitted>
  <last_update_submitted_qc>February 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Oral Vinorelbine</keyword>
  <keyword>Oral Chemotherapy</keyword>
  <keyword>Metastatic Breast Cancer</keyword>
  <keyword>Advanced Breast Cancer</keyword>
  <keyword>Maintenance treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Vinorelbine</mesh_term>
    <mesh_term>Vinblastine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

